Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Siga Technologies Inc's Business Segments
Siga Technologies Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
Single Reportable Segment
Total Revenue
$ 41
Countrys Reported
1
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
- Product Sales and Supportive Services0%
- US83.6%
- Non Us31.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 47 | - |
| Product Sales and Supportive Services | $ 41 | - |
| US | $ 34 | 83.6% |
1 more segments available
Sign in to unlock the full Siga Technologies Inc dataset.
Revenue Share by Country - FY
- US0%
Revenue by Geographic Country - FY
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 6 | - |
Revenue by Product & Service Category - FY
- Product Sales and Supportive Services56.7%
- Research and Development43.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product Sales and Supportive Services | $ 4 | 56.7% |
| Research and Development | $ 3 | 43.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
- Product Sales and Supportive Services0%
- US83.6%
- Non Us31.6%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 47 | - |
| Product Sales and Supportive Services | $ 41 | - |
| US | $ 34 | 83.6% |
1 more segments available
Sign in to unlock the full Siga Technologies Inc dataset.
Description of Siga Technologies Inc
Siga Technologies Inc. is a biotechnology company that specializes in the development and commercialization of pharmaceutical products for use in the defense, medical and research sectors. The company was founded in 1995 by Dr. Eric Rose, and is headquartered in New York, New York. Siga Technologies is publicly traded on the NASDAQ exchange under the ticker symbol SIGA.
The primary focus of Siga Technologies' research and development efforts is on the development of drugs that can be used to treat diseases caused by bioterrorism agents such as smallpox, Ebola, and anthrax. The company has developed a number of proprietary antiviral and antibiotic therapeutics that have undergone clinical trials and have been approved by the U.S. Food and Drug Administration (FDA). One such antiviral drug is TPOXX, which is used to treat smallpox infections and has been stockpiled by the U.S. Department of Health and Human Services.
Siga Technologies operates in two primary segments: government and commercial. The government segment focuses on developing and testing drugs for use in biodefense and public health preparedness, and includes contracts with agencies such as the Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority. The commercial segment focuses on exploring the use of Siga's drugs in other areas, such as the treatment of chronic viral diseases like hepatitis B and C.
The company has a strong commitment to research and development, and has formed partnerships with other biotechnology companies, academic institutions, and government agencies to advance its drug development programs. Siga Technologies employs a team of experienced researchers, scientists, and clinical experts who are committed to advancing the company's mission of developing effective treatments for infectious diseases.
Overall, Siga Technologies is a leading biotechnology company that specializes in developing highly effective drugs for use in the defense, medical, and research sectors. With its strong commitment to research and development and its focus on innovative drug development programs, the company is well-positioned to continue its growth and success in the years ahead.
The primary focus of Siga Technologies' research and development efforts is on the development of drugs that can be used to treat diseases caused by bioterrorism agents such as smallpox, Ebola, and anthrax. The company has developed a number of proprietary antiviral and antibiotic therapeutics that have undergone clinical trials and have been approved by the U.S. Food and Drug Administration (FDA). One such antiviral drug is TPOXX, which is used to treat smallpox infections and has been stockpiled by the U.S. Department of Health and Human Services.
Siga Technologies operates in two primary segments: government and commercial. The government segment focuses on developing and testing drugs for use in biodefense and public health preparedness, and includes contracts with agencies such as the Department of Defense, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority. The commercial segment focuses on exploring the use of Siga's drugs in other areas, such as the treatment of chronic viral diseases like hepatitis B and C.
The company has a strong commitment to research and development, and has formed partnerships with other biotechnology companies, academic institutions, and government agencies to advance its drug development programs. Siga Technologies employs a team of experienced researchers, scientists, and clinical experts who are committed to advancing the company's mission of developing effective treatments for infectious diseases.
Overall, Siga Technologies is a leading biotechnology company that specializes in developing highly effective drugs for use in the defense, medical, and research sectors. With its strong commitment to research and development and its focus on innovative drug development programs, the company is well-positioned to continue its growth and success in the years ahead.
Siga Technologies Inc. is a prominent player in the field of biotechnology, particularly in the realm of biodefense and public health solutions. The company is dedicated to developing innovative products and services that protect against biological threats. Below is an extensive overview of the segments, products, and services offered by Siga Technologies Inc. showcasing their comprehensive approach to addressing critical health and safety challenges.
Segments:
1. Biodefense:
Siga Technologies Inc. places a strong emphasis on biodefense, focusing on creating countermeasures against bioterrorism and emerging infectious diseases. This segment encompasses:
- Therapeutics Development: The company is engaged in the research, development, and commercialization of therapeutics aimed at preventing and treating smallpox, a significant concern in biodefense given its potential use as a bioweapon.
- Antiviral Drug Development: Siga conducts extensive research into antiviral medications targeting a range of viral pathogens, ensuring preparedness against potential outbreaks and enhancing public health responses.
2. Health:
The health segment of Siga Technologies is committed to enhancing patient outcomes and addressing critical medical needs. Its focus includes:
- Antibiotic Development: The company has initiated the development of a variety of antibiotics aimed at treating bacterial infections, particularly those caused by multidrug-resistant organisms such as MRSA (Methicillin-resistant Staphylococcus aureus).
- Innovative Therapeutics: By focusing on unmet medical needs, Siga actively seeks to innovate in areas like infectious diseases, aiming to provide effective medical solutions for conditions that are currently challenging to treat.
3. Agrochemicals:
Siga Technologies is also involved in the agrochemical sector, focusing on sustainable agricultural solutions. This segment consists of:
- Crop Yield Enhancement: The company develops products designed to improve crop yield, which is vital for food security and agriculture sustainability.
- Environmental Impact Reduction: Sigas agrochemical innovations aim to reduce the negative environmental impact associated with traditional agricultural practices, promoting eco-friendly solutions.
Products:
1. Smallpox Drug:
- Siga Technologies flagship product is a targeted therapeutic for the treatment and prevention of smallpox. This product has received approval from the US FDA, highlighting its importance as a biodefense tool, particularly for government stockpiles against potential smallpox outbreaks.
2. Antibacterial Drugs:
- The company offers a portfolio of antibiotics that address various bacterial infections, particularly those associated with antibiotic resistance. These drugs are critical in the fight against healthcare-associated infections.
3. Antiviral Drugs:
- Siga is actively involved in the research and development of antiviral drugs that target viral pathogens, enhancing the options available for treatment of viral infections.
4. Crop Protection Products:
- Siga Technologies has developed innovative crop protection solutions, including advanced fungicides aimed at safeguarding crops against fungal infections. These products contribute to healthier crops and are essential for sustainable farming practices.
Services:
1. Research and Development:
- Siga Technologies provides comprehensive research and development services across its key sectors of biodefense, health, and agrochemicals. The companys expertise in drug discovery and biotechnology enables the delivery of customized research solutions tailored to client needs.
2. Contract Manufacturing:
- The company offers state-of-the-art contract manufacturing services, particularly geared toward government agencies and other stakeholders within the biodefense sector. This includes the production of vaccines, biologics, and other critical healthcare products, emphasizing high-quality and scalable manufacturing capabilities.
3. Consulting Services:
- Siga Technologies provides consulting services to various clients in the biodefense, health, and agrochemical arenas. These services include strategic insights on product development processes, navigating regulatory landscapes, and supporting market entry strategies.
Conclusion:
Siga Technologies Inc. represents a multifaceted organization that is deeply invested in the research and development of innovative products and solutions to combat biological threats. With a firm focus on biodefense, health, and sustainable agricultural practices, Siga continues to push the boundaries of biotechnology, ensuring that critical therapeutic and preventive measures are in place to address some of the worlds most pressing health challenges. Through a combination of advanced therapeutics, robust research capabilities, and dedicated services, Siga is well-positioned to play a crucial role in global health security and agricultural sustainability.
Segments:
1. Biodefense:
Siga Technologies Inc. places a strong emphasis on biodefense, focusing on creating countermeasures against bioterrorism and emerging infectious diseases. This segment encompasses:
- Therapeutics Development: The company is engaged in the research, development, and commercialization of therapeutics aimed at preventing and treating smallpox, a significant concern in biodefense given its potential use as a bioweapon.
- Antiviral Drug Development: Siga conducts extensive research into antiviral medications targeting a range of viral pathogens, ensuring preparedness against potential outbreaks and enhancing public health responses.
2. Health:
The health segment of Siga Technologies is committed to enhancing patient outcomes and addressing critical medical needs. Its focus includes:
- Antibiotic Development: The company has initiated the development of a variety of antibiotics aimed at treating bacterial infections, particularly those caused by multidrug-resistant organisms such as MRSA (Methicillin-resistant Staphylococcus aureus).
- Innovative Therapeutics: By focusing on unmet medical needs, Siga actively seeks to innovate in areas like infectious diseases, aiming to provide effective medical solutions for conditions that are currently challenging to treat.
3. Agrochemicals:
Siga Technologies is also involved in the agrochemical sector, focusing on sustainable agricultural solutions. This segment consists of:
- Crop Yield Enhancement: The company develops products designed to improve crop yield, which is vital for food security and agriculture sustainability.
- Environmental Impact Reduction: Sigas agrochemical innovations aim to reduce the negative environmental impact associated with traditional agricultural practices, promoting eco-friendly solutions.
Products:
1. Smallpox Drug:
- Siga Technologies flagship product is a targeted therapeutic for the treatment and prevention of smallpox. This product has received approval from the US FDA, highlighting its importance as a biodefense tool, particularly for government stockpiles against potential smallpox outbreaks.
2. Antibacterial Drugs:
- The company offers a portfolio of antibiotics that address various bacterial infections, particularly those associated with antibiotic resistance. These drugs are critical in the fight against healthcare-associated infections.
3. Antiviral Drugs:
- Siga is actively involved in the research and development of antiviral drugs that target viral pathogens, enhancing the options available for treatment of viral infections.
4. Crop Protection Products:
- Siga Technologies has developed innovative crop protection solutions, including advanced fungicides aimed at safeguarding crops against fungal infections. These products contribute to healthier crops and are essential for sustainable farming practices.
Services:
1. Research and Development:
- Siga Technologies provides comprehensive research and development services across its key sectors of biodefense, health, and agrochemicals. The companys expertise in drug discovery and biotechnology enables the delivery of customized research solutions tailored to client needs.
2. Contract Manufacturing:
- The company offers state-of-the-art contract manufacturing services, particularly geared toward government agencies and other stakeholders within the biodefense sector. This includes the production of vaccines, biologics, and other critical healthcare products, emphasizing high-quality and scalable manufacturing capabilities.
3. Consulting Services:
- Siga Technologies provides consulting services to various clients in the biodefense, health, and agrochemical arenas. These services include strategic insights on product development processes, navigating regulatory landscapes, and supporting market entry strategies.
Conclusion:
Siga Technologies Inc. represents a multifaceted organization that is deeply invested in the research and development of innovative products and solutions to combat biological threats. With a firm focus on biodefense, health, and sustainable agricultural practices, Siga continues to push the boundaries of biotechnology, ensuring that critical therapeutic and preventive measures are in place to address some of the worlds most pressing health challenges. Through a combination of advanced therapeutics, robust research capabilities, and dedicated services, Siga is well-positioned to play a crucial role in global health security and agricultural sustainability.